1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Hodgson, S.H.; Mansatta, K.; Mallett, G.; Harris, V.; Emary, K.R.; Pollard, A.J. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect. Dis. 2021, 21, e26–e35. [Google Scholar] [CrossRef]
- Cook, T.; Roberts, J. Impact of vaccination by priority group on UK deaths, hospital admissions and intensive care admissions from COVID-19. Anaesthesia 2021, 76, 608–616. [Google Scholar] [CrossRef] [PubMed]
- Gee, J. First month of COVID-19 vaccine safety monitoring—United States, 14 December 2020–13 January 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70. [Google Scholar] [CrossRef] [PubMed]
- Brasil. COVID19—Painel Coronavírus 2021. Available online: https://covid.saude.gov.br (accessed on 29 June 2021).
- Lemos, D.R.Q.; D’angelo, S.M.; Farias, L.A.B.G.; Almeida, M.M.; Gomes, R.G.; Pinto, G.P.; Cavalcante Filho, J.N.; Feijão, L.X.; Cardoso, A.R.P.; Lima, T.B.R. Health system collapse 45 days after the detection of COVID-19 in Ceará, Northeast Brazil: A preliminary analysis. Rev. Soc. Bras. Med. Trop. 2020, 53, e20200354. [Google Scholar] [CrossRef] [PubMed]
- Lopez Bernal, J.; Andrews, N.; Gower, C.; Robertson, C.; Stowe, J.; Tessier, E.; Simmons, R.; Cottrell, S.; Roberts, R.; O’Doherty, M.; et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. BMJ 2021, 373, n1088. [Google Scholar] [CrossRef] [PubMed]
- Victora, C.; Castro, M.C.; Gurzenda, S.; de Medeiros, A.C.; França, G.; Barros, A.J.D. Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality. medRxiv 2021, 2021. [Google Scholar] [CrossRef]
- Ceará. Painel de Transparência—Vacinômetro Covid Ceará: Secretaria de Saúde do Estado do Ceará. 2021. Available online: https://integrasus.saude.ce.gov.br/#/indicadores/indicadores-coronavirus/vacinometro-covid (accessed on 25 June 2021).
- Christie, A.; Henley, S.J.; Mattocks, L.; Fernando, R.; Lansky, A.; Ahmad, F.B.; Adjemian, J.; Anderson, R.N.; Binder, A.M.; Carey, K.; et al. Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine—United States, 6 September 2020–1 May 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 858–864. [Google Scholar] [CrossRef] [PubMed]
- Roghani, A. The Influence of Covid-19 Vaccine on Daily Cases, Hospitalization, and Death Rate in Tennessee: A Case Study in the United States. medRxiv 2021, 2021. [Google Scholar] [CrossRef]
- Bolcato, M.; Aurilio, M.T.; Aprile, A.; Di Mizio, G.; Della Pietra, B.; Feola, A. Take-Home Messages from the COVID-19 Pandemic: Strengths and Pitfalls of the Italian National Health Service from a Medico-Legal Point of View. Healthcare 2021, 9, 17. [Google Scholar] [CrossRef] [PubMed]
- Pagliusi, S.; Hayman, B.; Jarrett, S. Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report. Vaccine 2021, 39, 2479–2488. [Google Scholar] [CrossRef] [PubMed]
- Voysey, M.; Clemens, S.A.C.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Bhorat, Q.E. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021, 397, 99–111. [Google Scholar] [CrossRef]
- Bolcato, M.; Trabucco Aurilio, M.; Di Mizio, G.; Piccioni, A.; Feola, A.; Bonsignore, A.; Tettamanti, C.; Ciliberti, R.; Rodriguez, D.; Aprile, A. The Difficult Balance between Ensuring the Right of Nursing Home Residents to Communication and Their Safety. Int. J. Environ. Res. Public Health 2021, 18, 2484. [Google Scholar] [CrossRef] [PubMed]
- Eccleston-Turner, M.; Upton, H. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility. Milbank Q. 2021. [Google Scholar] [CrossRef] [PubMed]
Variables | N | Deaths | % Deaths | Protection Ratio (95% CI) | Attributable Protection Ratio (%) (95%CI) |
---|---|---|---|---|---|
Number of doses and type of vaccine: | |||||
Oxford-AstraZeneca/Fiocruz 1st dose | 139,322 | 716 | 0.51 | 17.91 (16.55–19.39) | 94.4 (93.9–94.8) |
CoronaVac-Sinovac/Butantan 1st dose | 174,006 | 778 | 0.45 | 20.59 (19.07–22.22) | 95.1 (94.7–95.5) |
Vaccinated 1st dose | 313,328 | 1494 | 0.48 | 19.31 (18.20–20.48) | 94.8 (94.5–95.1) |
Oxford-AstraZeneca/Fiocruz 1st and 2nd dose | 27,193 | 3 | 0.01 | 834.45 (269.03–2588.18) | 99.8 (99.6–99.9) |
CoronaVac-Sinovac/Butantan 1st and 2nd dose | 132,777 | 108 | 0.08 | 113.17 (93.50–136.99) | 99.1 (98.9–99.3) |
Vaccinated 1st and 2nd dose | 159,970 | 111 | 0.07 | 132.67 (109.88–160.18 | 99.2 (99.1–99.4) |
Not vaccinated | 40,941 | 3769 | 9.21 | 1 | - |
Age Group–1st dose only: | |||||
75 to 79 years | |||||
Oxford-AstraZeneca/Fiocruz | 32,749 | 141 | 0.43 | 8.39 (7.03–10.00) | 88.0 (85.8–90.0) |
CoronaVac-Sinovac/Butantan | 97,072 | 481 | 0.50 | 7.29 (6.54–8.12) | 86.3 (84.7–87.7) |
Vaccinated | 129,821 | 622 | 0.48 | 7.53 (6.82–8.33) | 86.7 (85.3–88.0) |
Not vaccinated | 26,857 | 1010 | 3.76 | 1 | - |
80 to 89 years | |||||
Oxford-AstraZeneca/Fiocruz | 78,474 | 371 | 0.47 | 31.89 (28.59–35.58) | 96.8 (96.5–97.2) |
CoronaVac-Sinovac/Butantan | 70,327 | 256 | 0.36 | 41.42 (36.42–47.12) | 97.6 (97.2–97.9) |
Vaccinated | 148,801 | 627 | 0.42 | 35.78 (32.77–39.07) | 97.2 (96.9–97.4) |
Not vaccinated | 13,336 | 2011 | 15.08 | 1 | - |
90 years or more | |||||
Oxford-AstraZeneca/Fiocruz | 28,099 | 204 | 0.73 | 137.74 (120.13–157.92) | 99.2 (99.1–99.4) |
CoronaVac-Sinovac/Butantan | 6,607 | 41 | 0.62 | 161.14 (118.76–218.64) | 99.3 (99.1–99.5) |
Vaccinated | 34,706 | 245 | 0.71 | 141.65 (125.04–160.48) | 99.3 (99.2–99.4) |
Not vaccinated | 748 | 748 | 100.00 | 1 | - |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).